Expanded Access RBS2418 Treatment

Sponsor
Riboscience, LLC.
Study ID
NCT05683470
Status
No Longer Available

Conditions

  • Expanded Access in Pancreatic Cancer

Eligibility Criteria

Sex
FEMALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • RBS2418 — DRUG
    RBS2418 will be administered orally at 200 mg two times per day (BID).

Study Details

This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.

Key Dates

Status verified
Feb 2024